As expected, the binding of SPOA and BCR-ABL prevented BCR-ABL from recruiting GRB2, and reduced multiple signal activity, including RAS-MAPK, PI3K-AKT, STAT5, and CRKL, in imatinib sensitive and resistant CML cells. Here, AKT1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.